kabutan

CHUGAI PHARMACEUTICAL CO., LTD.(4519) Summary

4519
TSE Prime
CHUGAI PHARMACEUTICAL CO., LTD.
8,375
JPY
-72
(-0.85%)
Jan 29, 1:15 pm JST
54.71
USD
Jan 28, 11:15 pm EST
Result
PTS
outside of trading hours
8,363.7
Jan 29, 1:13 pm JST
Summary Chart Historical News Financial Result
PER
PBR
7.29
Yield
2.99%
Margin Trading Ratio
5.77
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
8,339 JPY 54.46 USD
Previous Close Jan 28
8,447 JPY 55.34 USD
High Jan 29, 11:25 am
8,430 JPY 55.05 USD
Low Jan 29, 9:01 am
8,275 JPY 54.04 USD
Volume
991,600
Trading Value
8.29B JPY 0.05B USD
VWAP
8355.92 JPY 54.59 USD
Minimum Trading Value
837,500 JPY 5,471 USD
Market Cap
14.06T JPY 0.09T USD
Number of Trades
4,858
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
7,010
1-Year High Aug 8, 2025
42,808
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 131,300 589,600 4.49
Jan 16, 2026 92,200 771,100 8.36
Jan 9, 2026 126,300 666,900 5.28
Dec 26, 2025 420,800 687,600 1.63
Dec 19, 2025 133,700 716,400 5.36
Company Profile
CHUGAI PHARMACEUTICAL CO., LTD. is a major pharmaceutical company. As a subsidiary of Roche, it has expanded its product line, including Tamiflu. The company's main focus is on anticancer drugs and rheumatoid arthritis treatments.
Sector
Pharmaceuticals
CHUGAI PHARMACEUTICAL CO., LTD. is a pharmaceutical company specializing in the research, development, manufacturing, and sales of pharmaceuticals, operating under the Swiss pharmaceutical giant Roche. In Japan, the company sells its own products through authorized dealers, while overseas it has sales bases in Europe, Taiwan, China, and other regions. Manufacturing is carried out at the company's domestic and international factories, as well as through contracted partners. As a member of the Roche Group, Chugai purchases some raw materials from Roche and distributes some products internationally through Roche's network. The company focuses on developing innovative drugs, particularly in the fields of cancer treatment and rheumatoid arthritis, while pursuing global business expansion.